US biotech OPKO Health has said it will continue with clinical development of its long-acting human growth hormone product (hGH-CTP), even though it has failed in a late stage trial in adul
Health plans, employers, and healthcare providers remain committed to adopting digital solutions and expect to increase their spending on the category, according to a recent poll.
